PX Space

Revolutionizing Ocular Health: Gaining Valuable Perspectives from Retina Specialist Dr. David Miller on Groundbreaking Care

July 06, 2023 Linda Robinson MSN, RN, CPXP Season 2 Episode 23
PX Space
Revolutionizing Ocular Health: Gaining Valuable Perspectives from Retina Specialist Dr. David Miller on Groundbreaking Care
Show Notes

In this episode, host Linda Robinson speaks with guest Dr. David Miller, the President of Retina Associates of Cleveland, Inc. Dr. Miller has a distinguished background, having completed a vitreoretinal surgery and diseases fellowship at Harvard University's Massachusetts Eye and Ear Infirmary. As the Medical Director of Cleveland Eye and Laser Surgery Center, which happens to be the largest retinal surgical facility in the region, Dr. Miller has established himself as a leading authority in the field.

During this episode, Dr. Miller delves into the topic of ocular health, providing insights into the treatment and prevention options for debilitating eye disorders and diseases, such as macular degeneration. Additionally, he sheds light on his groundbreaking work utilizing gene therapy to restore vision in blind pediatric patients. Dr. Miller also touches upon the future of ocular disease care, discussing concepts like genetic alteration, genetic supplementation to correct pharmacotherapy and genetic defect correction.

Dr. Miller's expertise has been consistently acknowledged by Best Doctors Inc., which includes him in their prestigious list of top retinal disease specialists since 2011. His accomplishments have also earned him recognition in Cleveland Magazine. Furthermore, Dr. Miller holds the esteemed distinction of being a charter member of the Retina Hall of Fame and a recipient of the Vitals Patients' Choice Award. His primary areas of focus lie within the realm of diabetic retinopathy, retinal detachment, and macular degeneration. Dr. Miller actively engages in various research studies and shares his knowledge on vitreoretinal diseases at local, national, and international platforms.